News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
DeepIP buys PatentMaker to lead European patent AI market
DeepIP, which raised $40M in nine months, acquires German patent workflow tool PatentMaker. The combined platform covers the full patent lifecycle for European IP teams.
Jeff Hughes Named CEO of 8am, LawPay Parent Company
Jeff Hughes, a 30-year software executive, takes over as CEO of 8am after leading Enverus through 6x revenue growth. Here's what changes for law practice management users.
Legal firms assess AI in-house: Erste Bank leads strategy work
Andrea Miskolczi of InterAlia Consulting discusses AI readiness audits with enterprise legal teams at Lexpo Amsterdam. Learn what in-house assessments reveal about adoption readiness.
Your lawyers are uploading client data to ChatGPT right now
70% of law firms lack AI policies, leaving sensitive data exposed via unsanctioned tools. Browser-level controls can prevent it — here's what to audit first.
Clarivate Names Simon Webster as IP Segment President
Simon Webster takes the helm of Clarivate's intellectual property division. The appointment signals focus on patent analytics and trademark management in competitive markets.
Define your biologics formulation upfront to cut late-stage redesigns
Quality by Design (QbD) frameworks let biologic developers lock in stability and manufacturability early. Here's how to align formulation strategy with clinical needs before scale-up.
Cell Therapy Programs Need Assay Plans Before Clinical Trials
Deferring analytical development early is a common cause of FDA Complete Response Letters. Here's why process characterization must start in the lab, not scale-up.
Your CDMO choice shapes program risk—here's how to spot which reduces it
One-site operations with embedded project teams cut handoffs and communication gaps that quietly compound delays. How to assess your partner's risk design before signing.
Cell Therapy CDMO Market to Hit $143.6B by 2034 — What Sponsors Now Demand
The cell and gene therapy market is growing at 31% annually through 2034, pushing sponsors to outsource manufacturing early. Here's what CDMOs must prove to win deals.
Roche pays $2.3B for blood cancer drug that degrades BTK protein
Roche and Nurix licensed bexobrutideg, an oral BTK degrader, in a deal worth up to $2.3 billion. The drug targets B-cell malignancies and enters Phase III trials this summer.
Incyte pays $2bn for VGA039, a monthly shot for bleeding disorders
Incyte will spend up to $2 billion to acquire Vega Therapeutics and its late-stage von Willebrand disease candidate. The drug could displace frequent IV infusions with once-monthly dosing.
90% of blockbuster drugs lack biosimilar competitors—why pricing kills the pipeline
A 2025 IQVIA analysis found 90% of biologics losing patent protection this decade have no biosimilar in development. Samsung Bioepis exec explains why: broken economics, not broken science.